Chronic Lymphocytic Leukemia (CLL) Prognostic Panel, Comprehensive
Use
This comprehensive prognostic panel is used for determining prognosis and risk stratification in patients with chronic lymphocytic leukemia (CLL). It integrates multiple prognostic markers—including chromosome analysis, a 6‑marker FISH panel, IgVH gene mutation analysis, ZAP‑70, CD38, and serum β2‑microglobulin—to generate a patient‑specific overall risk interpretation that reflects the combined prognostic power of each marker ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq41?utm_source=openai)).
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Other
Biomarkers
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
16 mL (10 mL minimum)
Minimum Volume
Not provided
Container
sodium heparin (green‑top) tube
Other tests from different labs that may be relevant